Robert A. Chase

Medicine · Health Sciences

32h-index3.7kcitations209works2.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(43), Orthopedic Surgery and Rehabilitation(25), HIV/AIDS drug development and treatment(24), Hepatitis B Virus Studies(23), Reconstructive Surgery and Microvascular Techniques(14)

Publications209 total

A Pragmatic Approach to Streamlining Single-Use Plastics in Health Care
Annals of Internal Medicine·2025· 1 cited
WAS THERE INCREASED INPATIENT GASTROSTOMY TUBE PLACEMENT DURING THE 2020 COVID-19 PANDEMIC?
Gastrointestinal Endoscopy·2023Open Access
WAS THERE INCREASED INPATIENT GASTROSTOMY TUBE PLACEMENT DURING THE 2020 COVID-19 PANDEMIC?
Gastrointestinal Endoscopy·2023Open Access
WAS THERE INCREASED INPATIENT GASTROSTOMY TUBE PLACEMENT DURING THE 2020 COVID-19 PANDEMIC?
Gastrointestinal Endoscopy·2023Open Access
Implementation of point-of-care blood gas testing at a large community hospital: Cost analysis, sepsis bundle compliance, and employee engagement
Canadian Journal of Respiratory Therapy·2021· 3 citedOpen Access
Art and War in the Pacific World: Making, Breaking, and Taking from Anson's Voyage to the Philippine-American War
Journal of American History·2020
A Systems Approach to Impact Management
2020
Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2
Antimicrobial Agents and Chemotherapy·2019· 3 citedOpen Access
Socioeconomic Impact Management
2019· 3 cited
Planning for Impact Management: A Systems Perspective
2019
Assessing the Economic and Fiscal Effects of Repository Siting
2019
<i>In Vitro</i> Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A
Antimicrobial Agents and Chemotherapy·2018· 6 citedOpen Access
Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse
Infection and Drug Resistance·2018· 7 citedOpen Access
Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons
Antimicrobial Agents and Chemotherapy·2017· 23 citedOpen Access
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study
Hepatology·2017· 75 citedOpen Access
Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a
Journal of Biological Chemistry·2017· 12 citedOpen Access
Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibld Study
Blood·2016· 1 cited
Lack of Interaction Between Elbasvir/Grazoprevir and Approved HIV and HBV Drugs in Viral Replication In Vitro.
IDWeek 2016·2016
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons
Antimicrobial Agents and Chemotherapy·2016· 57 citedOpen Access
Lack of Interaction Between Elbasvir/Grazoprevir and Approved HIV and Hepatitis B Virus Drugs in Viral Replication In Vitro
Open Forum Infectious Diseases·2016· 1 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Angela Skelton(8), F. George Njoroge(8), Paul Ingravallo(7), Andrew Prongay(7), John Pichardo(6), Xiao Tong(6), Srikanth Venkatraman(6), Stéphane Bogen(6), Sony Agrawal(6), Bruce A. Malcolm(5), Ellen Xia(5), Viyyoor Girijavallabhan(5), Patricia McMonagle(5), Frederick Lahser(4), Andrea Hart(4), Anil K. Saksena(4), Jacquelyn Wright-Minogue(4), Christine Risano(4), Stephanie Curry(4), Ashok Arasappan(3)